Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial
- PMID: 17301099
- DOI: 10.1183/09031936.00146306
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial
Abstract
Evidence suggests that eosinophilic airway inflammation is important in the pathogenesis of severe chronic obstructive pulmonary disease (COPD) exacerbations. The present authors tested the hypothesis that a management strategy that aims to reduce sputum eosinophil counts is associated with a reduction in exacerbations of COPD. A total of 82 patients with COPD were randomised into two groups. One group was treated according to traditional guidelines (British Thoracic Society (BTS) group) and the other (sputum group) was treated with the additional aim of minimising eosinophilic airway inflammation, assessed using the induced sputum eosinophil count. The primary outcome was exacerbations, which were categorised as mild, moderate or severe. The frequency of severe exacerbations per patient per year was 0.5 and 0.2 in the BTS and sputum groups, respectively (mean reduction 62%). The majority of this benefit was confined to patients with eosinophilic airway inflammation. There was no difference in the frequency of mild and moderate exacerbations. The average daily dose of inhaled or oral corticosteroids during the trial did not differ between the groups. Out of 42 patients in the sputum group, 17 required regular oral corticosteroids to minimise eosinophilic airway inflammation. A management strategy that aims to minimise eosinophilic airway inflammation, as well as symptoms, is associated with a reduction in severe exacerbations of chronic obstructive pulmonary disease.
Comment in
-
Same role and same treatment for airway eosinophilia in asthma and COPD?Eur Respir J. 2007 May;29(5):831-3. doi: 10.1183/09031936.00022507. Eur Respir J. 2007. PMID: 17470618 No abstract available.
Similar articles
-
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.Lancet. 2002 Nov 30;360(9347):1715-21. doi: 10.1016/S0140-6736(02)11679-5. Lancet. 2002. PMID: 12480423 Clinical Trial.
-
Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.Thorax. 2005 Mar;60(3):193-8. doi: 10.1136/thx.2004.032516. Thorax. 2005. PMID: 15741434 Free PMC article. Clinical Trial.
-
Lung function decline and variable airway inflammatory pattern: longitudinal analysis of severe asthma.J Allergy Clin Immunol. 2014 Aug;134(2):287-94. doi: 10.1016/j.jaci.2014.04.005. Epub 2014 Jun 11. J Allergy Clin Immunol. 2014. PMID: 24928647
-
Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary disease.Proc Am Thorac Soc. 2004;1(3):152-60. doi: 10.1513/pats.200402-003MS. Proc Am Thorac Soc. 2004. PMID: 16113428 Review.
-
Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.Pharmacol Ther. 2017 Jan;169:57-77. doi: 10.1016/j.pharmthera.2016.10.016. Epub 2016 Oct 20. Pharmacol Ther. 2017. PMID: 27773786 Review.
Cited by
-
Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis. 2015 Jun 17;10:1155-61. doi: 10.2147/COPD.S80992. eCollection 2015. Int J Chron Obstruct Pulmon Dis. 2015. PMID: 26124655 Free PMC article.
-
Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide.Inflammation. 2013 Oct;36(5):1178-85. doi: 10.1007/s10753-013-9653-8. Inflammation. 2013. PMID: 23681903
-
Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease.J Clin Med. 2020 Aug 18;9(8):2670. doi: 10.3390/jcm9082670. J Clin Med. 2020. PMID: 32824775 Free PMC article. Review.
-
Effects of inhaled corticosteroids (ICS) on lung microbiota and local immune response in long-term treatment of chronic obstructive pulmonary disease (COPD): utility of titration and therapeutic index.Naunyn Schmiedebergs Arch Pharmacol. 2022 Jul;395(7):849-858. doi: 10.1007/s00210-022-02237-z. Epub 2022 Apr 18. Naunyn Schmiedebergs Arch Pharmacol. 2022. PMID: 35435466
-
Approach to chronic obstructive pulmonary disease in primary care.Can Fam Physician. 2008 May;54(5):706-11. Can Fam Physician. 2008. PMID: 18474704 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical